Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (171-180 of 205) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyFederica Grosso, Robin L Jones, George D Demetri, et al.
Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
The American Journal of Surgical Pathology|September 18, 2012
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangementCheng-Han Lee, Rola H Ali, Marjan Rouzbahman, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Gastroenterology|April 14, 2015
Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1Yujiro Hayashi, Michael R Bardsley, Yoshitaka Toyomasu, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
Pageof 21

Showing results (171-180 of 205) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyFederica Grosso, Robin L Jones, George D Demetri, et al.
Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
The American Journal of Surgical Pathology|September 18, 2012
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangementCheng-Han Lee, Rola H Ali, Marjan Rouzbahman, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Gastroenterology|April 14, 2015
Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1Yujiro Hayashi, Michael R Bardsley, Yoshitaka Toyomasu, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
Pageof 21